| scholarly article | Q13442814 |
| P2093 | author name string | Zdenek Berger | |
| Kelsey A Smith | |||
| Matthew J Lavoie | |||
| P2860 | cites work | Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity | Q22254785 |
| GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease | Q24294785 | ||
| The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity | Q24297634 | ||
| The R1441C mutation of LRRK2 disrupts GTP hydrolysis | Q24303406 | ||
| Kinase activity of mutant LRRK2 mediates neuronal toxicity | Q24303603 | ||
| Homo- and heterodimerization of ROCO kinases: LRRK2 kinase inhibition by the LRRK2 ROCO fragment | Q24310262 | ||
| The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites | Q24313336 | ||
| Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways | Q24316917 | ||
| The familial Parkinsonism gene LRRK2 regulates neurite process morphology | Q24317613 | ||
| The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation | Q24318533 | ||
| Localization of LRRK2 to membranous and vesicular structures in mammalian brain | Q24318643 | ||
| The Parkinson disease-associated protein kinase LRRK2 exhibits MAPKKK activity and phosphorylates MKK3/6 and MKK4/7, in vitro | Q24322792 | ||
| LRRK2 regulates synaptic vesicle endocytosis | Q24336523 | ||
| LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study | Q39086510 | ||
| Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants | Q39223630 | ||
| Apoptotic mechanisms in mutant LRRK2-mediated cell death | Q40149547 | ||
| The presenilin proteins are components of multiple membrane-bound complexes that have different biological activities | Q40559975 | ||
| Complex N-linked glycosylated nicastrin associates with active gamma-secretase and undergoes tight cellular regulation | Q40716855 | ||
| Kinetic mechanistic studies of wild-type leucine-rich repeat kinase 2: characterization of the kinase and GTPase activities | Q42737973 | ||
| Differential effects of divalent manganese and magnesium on the kinase activity of leucine-rich repeat kinase 2 (LRRK2). | Q43141823 | ||
| Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin | Q44511126 | ||
| Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation | Q46587417 | ||
| Investigation of leucine-rich repeat kinase 2 : enzymological properties and novel assays. | Q54781213 | ||
| Parkinson's disease | Q56877819 | ||
| Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation | Q57373779 | ||
| Phosphorylase kinase from rabbit skeletal muscle: identification of the calmodulin-binding subunits | Q71533236 | ||
| Dopamine covalently modifies and functionally inactivates parkin | Q24338423 | ||
| Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity | Q24338647 | ||
| Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells | Q24651391 | ||
| LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model | Q24656256 | ||
| Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase | Q27649733 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Sequence and structure-based prediction of eukaryotic protein phosphorylation sites | Q28140445 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| Differential regulation and properties of MAPKs | Q28301932 | ||
| Leucine-rich repeat kinase 2 associates with lipid rafts | Q28591286 | ||
| Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation | Q29614227 | ||
| Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study | Q29614953 | ||
| Kinase activity is required for the toxic effects of mutant LRRK2/dardarin | Q29620478 | ||
| Wild-type LRRK2 but not its mutant attenuates stress-induced cell death via ERK pathway | Q30438387 | ||
| The Gly2019Ser mutation in LRRK2 is not fully penetrant in familial Parkinson's disease: the GenePD study | Q30440660 | ||
| Detection of phosphoproteins on electroblot membranes using a small-molecule organic fluorophore | Q33205608 | ||
| Identification of the autophosphorylation sites of LRRK2. | Q33510233 | ||
| The WD40 domain is required for LRRK2 neurotoxicity | Q33521241 | ||
| Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. | Q33594388 | ||
| Cryoelectron microscopy structure of purified gamma-secretase at 12 A resolution | Q33694348 | ||
| LRRK1 protein kinase activity is stimulated upon binding of GTP to its Roc domain | Q34461973 | ||
| Mutations in LRRK2/dardarin associated with Parkinson disease are more toxic than equivalent mutations in the homologous kinase LRRK1. | Q34613694 | ||
| γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, aph-1, and pen-2 | Q34648460 | ||
| Mixed-lineage kinase control of JNK and p38 MAPK pathways | Q34810173 | ||
| The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity | Q36154267 | ||
| How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease | Q36310520 | ||
| Genetics of Parkinson disease: paradigm shifts and future prospects. | Q36423921 | ||
| Mitochondrial complex I: structure, function and pathology | Q36534792 | ||
| Substrate specificity and inhibitors of LRRK2, a protein kinase mutated in Parkinson's disease | Q37139305 | ||
| The regulation of extracellular signal-regulated kinase (ERK) in mammalian cells | Q37194140 | ||
| Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions | Q37225356 | ||
| Update on the functional biology of Lrrk2. | Q37395783 | ||
| Dependence of leucine-rich repeat kinase 2 (LRRK2) kinase activity on dimerization | Q37479332 | ||
| P433 | issue | 26 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phosphorylation | Q242736 |
| Leucine rich repeat kinase 2 | Q409961 | ||
| identical protein binding | Q14762994 | ||
| P304 | page(s) | 5511-23 | |
| P577 | publication date | 2010-07-06 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Membrane localization of LRRK2 is associated with increased formation of the highly active LRRK2 dimer and changes in its phosphorylation | |
| P478 | volume | 49 |
| Q39663092 | 14-3-3 proteins are promising LRRK2 interactors |
| Q38832778 | A High-Throughput Screen to Identify LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease Using RapidFire Mass Spectrometry |
| Q41776543 | A Link between Autophagy and the Pathophysiology of LRRK2 in Parkinson's Disease |
| Q47127108 | A homologue of the Parkinson's disease-associated protein LRRK2 undergoes a monomer-dimer transition during GTP turnover |
| Q26746897 | Activation Mechanism of LRRK2 and Its Cellular Functions in Parkinson's Disease |
| Q89611946 | Advances in elucidating the function of leucine-rich repeat protein kinase-2 in normal cells and Parkinson's disease |
| Q90292515 | Allosteric modulation of the GTPase activity of a bacterial LRRK2 homolog by conformation-specific Nanobodies |
| Q33985278 | Arsenite stress down-regulates phosphorylation and 14-3-3 binding of leucine-rich repeat kinase 2 (LRRK2), promoting self-association and cellular redistribution |
| Q24298093 | Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers |
| Q51765180 | Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins |
| Q37686991 | Contribution of GTPase activity to LRRK2-associated Parkinson disease |
| Q26827527 | Current Understanding Of LRRK2 In Parkinson’s Disease: Biochemical And Structural Features And Inhibitor Design |
| Q24299578 | Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways |
| Q24305419 | Dominant-negative effects of LRRK2 heterodimers: A possible mechanism of neurodegeneration in Parkinson’s disease caused by LRRK2 I2020T mutation |
| Q36325667 | Evolution of Neurodegeneration |
| Q60917742 | Functional and behavioral consequences of Parkinson's disease-associated G2019S mutation |
| Q24339009 | G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization |
| Q39269900 | GTP binding and intramolecular regulation by the ROC domain of Death Associated Protein Kinase 1. |
| Q24310620 | GTP binding controls complex formation by the human ROCO protein MASL1 |
| Q36006905 | GTP-binding Protein-like Domain of AGAP1 Is Protein Binding Site That Allosterically Regulates ArfGAP Protein Catalytic Activity |
| Q21144926 | GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1 |
| Q24306167 | GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2 |
| Q38225040 | Genetic, structural, and molecular insights into the function of ras of complex proteins domains. |
| Q27013695 | Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications |
| Q38044437 | Human leucine-rich repeat kinase 1 and 2: intersecting or unrelated functions? |
| Q64785219 | Induced pluripotent stem cell-based modeling of mutant LRRK2-associated Parkinson's disease |
| Q58735690 | Insights into the Influence of Specific Splicing Events on the Structural Organization of |
| Q24322747 | Interplay of LRRK2 with chaperone-mediated autophagy |
| Q36477677 | Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity |
| Q42321517 | LRP-1 and LRP-2 receptors function in the membrane neuron. Trafficking mechanisms and proteolytic processing in Alzheimer's disease |
| Q55410950 | LRRK 2 gene mutations in the pathophysiology of the ROCO domain and therapeutic targets for Parkinson's disease: a review. |
| Q92173150 | LRRK2 Biology from structure to dysfunction: research progresses, but the themes remain the same |
| Q38620229 | LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand? |
| Q38501861 | LRRK2 Pathways Leading to Neurodegeneration |
| Q38044446 | LRRK2 and autophagy: a common pathway for disease. |
| Q54976406 | LRRK2 and mitochondria: Recent advances and current views. |
| Q38044441 | LRRK2 and vesicle trafficking |
| Q28078248 | LRRK2 at the interface of autophagosomes, endosomes and lysosomes |
| Q36385349 | LRRK2 autophosphorylation enhances its GTPase activity |
| Q39137339 | LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. |
| Q33999270 | LRRK2 kinase activity is dependent on LRRK2 GTP binding capacity but independent of LRRK2 GTP binding |
| Q24298891 | LRRK2 kinase activity regulates synaptic vesicle trafficking and neurotransmitter release through modulation of LRRK2 macro-molecular complex |
| Q38253871 | LRRK2 pathobiology in Parkinson's disease |
| Q47362838 | LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network |
| Q42288293 | LRRK2 phosphorylates pre-synaptic N-ethylmaleimide sensitive fusion (NSF) protein enhancing its ATPase activity and SNARE complex disassembling rate |
| Q38218398 | LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis |
| Q37635000 | LRRK2: Cause, Risk, and Mechanism |
| Q36888947 | LRRK2: an éminence grise of Wnt-mediated neurogenesis? |
| Q38009436 | Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease |
| Q37829776 | Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? |
| Q37996364 | Mechanisms of LRRK2-Mediated Neurodegeneration |
| Q39137358 | Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation. |
| Q33920691 | Membrane recruitment of endogenous LRRK2 precedes its potent regulation of autophagy |
| Q35799109 | Mitochondrial dysfunction in genetic animal models of Parkinson's disease |
| Q34986076 | Models for LRRK2-Linked Parkinsonism |
| Q51082151 | Molecular Insights and Functional Implication of LRRK2 Dimerization |
| Q40733668 | Multiple regulatory mechanisms for the Dictyostelium Roco protein GbpC. |
| Q34086842 | Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration |
| Q38430373 | New insights on Parkinson's disease genes: the link between mitochondria impairment and neuroinflammation |
| Q34637362 | Novel ethyl methanesulfonate (EMS)-induced null alleles of the Drosophila homolog of LRRK2 reveal a crucial role in endolysosomal functions and autophagy in vivo |
| Q36010883 | Number and brightness analysis of LRRK2 oligomerization in live cells |
| Q40116327 | Parkinson disease-associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response. |
| Q27687171 | Parkinson's disease and immune system: is the culprit LRRKing in the periphery? |
| Q36037105 | Parkinson's disease-linked LRRK2 is expressed in circulating and tissue immune cells and upregulated following recognition of microbial structures |
| Q64864829 | Parkinson's disease: what the model systems have taught us so far |
| Q38044439 | Phosphorylation of LRRK2: from kinase to substrate |
| Q38182492 | Prediction of the repeat domain structures and impact of parkinsonism-associated variations on structure and function of all functional domains of leucine-rich repeat kinase 2 (LRRK2). |
| Q27308060 | Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice |
| Q37918059 | Proteostasis and Movement Disorders: Parkinson's Disease and Amyotrophic Lateral Sclerosis |
| Q42803700 | Re-examination of the dimerization state of leucine-rich repeat kinase 2: predominance of the monomeric form |
| Q35997636 | Regulation of Physiologic Actions of LRRK2: Focus on Autophagy |
| Q60951726 | Roco Proteins and the Parkinson's Disease-Associated LRRK2 |
| Q60921580 | Roco Proteins: GTPases with a Baroque Structure and Mechanism |
| Q34300430 | Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease |
| Q34192817 | Role of LRRK2 kinase dysfunction in Parkinson disease |
| Q35771011 | Roles of the Drosophila LRRK2 homolog in Rab7-dependent lysosomal positioning |
| Q36015579 | Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. |
| Q98182370 | Splice-Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice |
| Q38213378 | Structural biology of the LRRK2 GTPase and kinase domains: implications for regulation |
| Q28116245 | Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts |
| Q48132251 | Synthesis and In Vitro and In Vivo Evaluation of [3H]LRRK2-IN-1 as a Novel Radioligand for LRRK2. |
| Q91635012 | The Emerging Functions of LRRK2 and Rab GTPases in the Endolysosomal System |
| Q55442883 | The Enzymatic Core of the Parkinson’s Disease-Associated Protein LRRK2 Impairs Mitochondrial Biogenesis in Aging Yeast. |
| Q24324345 | The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation |
| Q33905778 | The LRRK2 G2385R variant is a partial loss-of-function mutation that affects synaptic vesicle trafficking through altered protein interactions. |
| Q47225650 | The LRRK2 signalling system |
| Q38111307 | The Neurobiology of LRRK2 and its Role in the Pathogenesis of Parkinson’s Disease |
| Q64786590 | The Parkinson's disease-associated mutation N1437H impairs conformational dynamics in the G domain of LRRK2 |
| Q38482479 | The Role of α-Synuclein and LRRK2 in Tau Phosphorylation |
| Q26853537 | The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease |
| Q91775798 | The dynamic switch mechanism that leads to activation of LRRK2 is embedded in the DFGψ motif in the kinase domain |
| Q28481326 | The nitric oxide-cyclic GMP pathway regulates FoxO and alters dopaminergic neuron survival in Drosophila |
| Q36325701 | The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease |
| Q64811522 | The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors |
| Q64859135 | The unlikely partnership between LRRK2 and α-synuclein in Parkinson's disease |
| Q39206431 | Understanding the GTPase Activity of LRRK2: Regulation, Function, and Neurotoxicity. |
| Q92284349 | Vitamin B12 modulates Parkinson's disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection |
Search more.